LOS ANGELES, CALIFORNIA – December 29, 2021 – GTX Corp (OTC: GTXO) (“GTX” or the “Company”), a pioneer in the field of health and safety wearable GPS human and asset tracking systems and a supplier of personal protective medical equipment, announced today that it has begun sales and distribution of asymptomatic COVID screening tests.
This simple, noninvasive screening test provides results immediately with 96.8% accuracy, there is no need to go to a lab or wait hours or days for your results. This is an affordable and convenient home, office, or school early prescreening solution for anyone who wants or needs to know if they may have been infected with the virus even before showing any symptoms.
- Asymptomatic screening at PCR levels.
- 96.8% Accurate.
- Non-invasive – safer and much less painful than standard nasal swab.
- Easy self-administered through a simple smell test and app, no waiting in long lines.
- No medical staff needed to administer.
- Takes less than 1 minute with immediate results.
- Digital time stamped record of the test for proof and validation.
- Digital Real-time, authenticated passes which can be stored on your phone and verified at all building and room entry points.
“GTX’s experience and success marketing PPE including antibody and antigen test kits, makes them a perfect partner for us to address the urgent need for early screening. To date 85% of COVID-19 cases experience the partial loss of smell in days 1-3, as opposed to the other symptoms emerging in days 5-9. The virus and variants gather in the olfactory gland’s receptors and can be early detected using smell tests,” stated Marc Bookman, Opu Labs CEO.
“We are very excited to introduce this innovative, affordable, quick, safe, and easy prescreening digital smell test. It is the ultimate early detection solution to usher in the new normal way of life with COVID-19. Peace of mind never smelled so good,” stated Patrick Bertagna, GTX Corp CEO.
Widely known for its patented GPS SmartSole and Smartphone GPS Tracking App, GTX also distributes an extensive line of Personal Protective Equipment “PPE”, owns and licenses a large portfolio of patents in the GPS and wearable technology space, and is a GSA-approved military and government supplier. Many of the Company’s products are available at its online store and Amazon. To find out more about how you can buy or become an authorized reseller of GTX products, contact our info@gtxcorp.com business development office.
About Opu Labs, Inc.
Opu Labs markets and develops AI and blockchain based health and wellness applications. The company’s services help consumers analyze their health as well as manage, monitor, and monetize their health data. Opu AI technology analyzes images of the face and skin to assess health conditions, aging, as well as the risk of viral infections including COVID-19. In addition, Opu Labs is an authorized global direct partner for Corowell’s olfactory (smell) test. With the benefits of security, privacy, and control, the Opu Platform provides a transparent and efficient data marketplace for decentralized healthcare information. Opu Labs is set out to improve how the global healthcare industry exchanges data, information, and rewards in a way that benefits patients, doctors, manufacturers, and service providers.
MetAlert (OTC: MLRT) and its subsidiaries occupy a commanding position in the design, development, manufacturing, distribution, sales, and licensing of GPS wearable technology, asset recovery services, wandering assistive technology, and health data collection and monitoring. The Company delivers comprehensive global solutions encompassing logistics, hardware, software, and connectivity.
Notable achievements include GunAlert the world’s first all in one firearm safety solution gun lock with patented motion sensor and GPS theft recovery. And the groundbreaking GPS SmartSole®, a fusion of Dr. Scholl’s comfort with LoJack’s tracking prowess. It stands as the world’s inaugural invisible wearable tracking device, designed for individuals susceptible to wandering due to Alzheimer’s, dementia, autism, and traumatic brain injury. MetAlert’s subscription-based model thrives on technology innovation fortified by intellectual property safeguards. The company boasts international distribution channels serving customers across 40 countries, alongside its role as a U.S. Military Government contractor. In addition to public health entities, MetAlert caters to municipalities, emergency and law enforcement agencies, private educational institutions, assisted living facilities, NGOs, senior care residences, consumers, and small enterprises.
General information, investor relations, wholesale licensing, consumer purchase:
213.489.3019 | Info@MetAlert.com | IR@MetAlert.com | Contact Us
MetAlert.com | Mygunalert.com | Track My Workforce | GPS SmartSole.com
MetAlert United Kingdom– In the UK, MetAlert operates from its London office.
Please contact: Nelson Skip Riddle | Email: NSRiddle@MetAlert.com | Tel: +44 7785 364100
Level 2 Security (Wholly owned subsidiary) Email: contactus@level2sec.com | www.mygunalert.com | www.ifitmoves.com
Forward Looking Statements
This news release contains forward-looking statements. The terms and phrases “expects,” “would,” “will,” “believes,” and similar terms and phrases are intended to identify these forward-looking statements. Forward-looking statements are based on estimates and assumptions made by MetAlert considering its experience and perception of current conditions and expected future developments, as well as other factors that MetAlert believes are appropriate in the circumstances. Many factors could cause MetAlert’s actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Certain risk factors that may cause actual results to differ are outlined in MetAlert’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (which may be obtained on the SEC Website). These factors should be considered carefully, and readers should not rely on MetAlert’s forward-looking statements. MetAlert has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required.
Disclaimer: MetAlert does not warrant or represent that the unauthorized use of materials drawn from this document’s content will not infringe the rights of third parties who are not owned or affiliated by MetAlert. Further, MetAlert cannot be held responsible or liable for the unauthorized use of this document’s content by third parties unknown to the company.